IL280584B2 - Adjuvant effect of the tlr1/2 agonist diprovocim synergizes with checkpoint-inhibiting antibodies to eliminate disease - Google Patents

Adjuvant effect of the tlr1/2 agonist diprovocim synergizes with checkpoint-inhibiting antibodies to eliminate disease

Info

Publication number
IL280584B2
IL280584B2 IL280584A IL28058421A IL280584B2 IL 280584 B2 IL280584 B2 IL 280584B2 IL 280584 A IL280584 A IL 280584A IL 28058421 A IL28058421 A IL 28058421A IL 280584 B2 IL280584 B2 IL 280584B2
Authority
IL
Israel
Prior art keywords
cells
immunizing
diprovocim
use according
pharmacological composition
Prior art date
Application number
IL280584A
Other languages
English (en)
Hebrew (he)
Other versions
IL280584B1 (en
IL280584A (en
Inventor
Bruce Beutler
Ying Wang
Original Assignee
Univ Texas
Bruce Beutler
Ying Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Bruce Beutler, Ying Wang filed Critical Univ Texas
Publication of IL280584A publication Critical patent/IL280584A/en
Publication of IL280584B1 publication Critical patent/IL280584B1/en
Publication of IL280584B2 publication Critical patent/IL280584B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001118—Receptors for colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001121—Receptors for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001124—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001128—CD44 not IgG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001131—Epidermal growth factor [EGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001158—Proteinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001158—Proteinases
    • A61K39/001159—Matrix metalloproteinases [MMP]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
IL280584A 2018-08-02 2019-07-31 Adjuvant effect of the tlr1/2 agonist diprovocim synergizes with checkpoint-inhibiting antibodies to eliminate disease IL280584B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862713823P 2018-08-02 2018-08-02
PCT/US2019/044421 WO2020028532A1 (en) 2018-08-02 2019-07-31 Adjuvant effect of the tlr1/2 agonist diprovocim synergizes with checkpoint-inhibiting antibodies to eliminate disease

Publications (3)

Publication Number Publication Date
IL280584A IL280584A (en) 2021-03-25
IL280584B1 IL280584B1 (en) 2025-02-01
IL280584B2 true IL280584B2 (en) 2025-06-01

Family

ID=69232110

Family Applications (1)

Application Number Title Priority Date Filing Date
IL280584A IL280584B2 (en) 2018-08-02 2019-07-31 Adjuvant effect of the tlr1/2 agonist diprovocim synergizes with checkpoint-inhibiting antibodies to eliminate disease

Country Status (10)

Country Link
US (1) US20210315992A1 (enExample)
EP (1) EP3829571B1 (enExample)
JP (1) JP2021533134A (enExample)
KR (1) KR20210029280A (enExample)
CN (1) CN113164445A (enExample)
AU (2) AU2019315952A1 (enExample)
BR (1) BR112021001992A2 (enExample)
CA (1) CA3108515A1 (enExample)
IL (1) IL280584B2 (enExample)
WO (1) WO2020028532A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11938182B2 (en) 2020-03-26 2024-03-26 Provectus Pharmatech, Inc. Halogenated xanthenes as vaccine adjuvants
EP4103283A4 (en) 2020-03-26 2024-02-28 Provectus Pharmatech, Inc. NEW USES OF HALOGENATED XANTHENES IN ONCOLOGY AND VIROLOGY
CN115666553A (zh) * 2020-05-27 2023-01-31 轴向治疗公司 Tlr2调节剂化合物及其药物组合物和用途
US20230210925A1 (en) * 2020-07-14 2023-07-06 Dic Corporation Composition for cytotoxic t lymphocyte (ctl) activation
WO2023212650A1 (en) * 2022-04-29 2023-11-02 The Scripps Research Institute Next generation diprovocims that activate the innate and adaptive immune response

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014163684A1 (en) * 2013-04-03 2014-10-09 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2018005812A1 (en) * 2016-06-29 2018-01-04 The Scripps Research Institute Diprovocims: a new and potent class of tlr agonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US5180806A (en) 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods
US6489354B1 (en) 1999-03-02 2002-12-03 Merck & Co., Inc. 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity
US6942866B2 (en) 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
ATE361068T1 (de) * 2001-08-08 2007-05-15 Pentraxin Therapeutics Ltd Wirkstoff zur entfernung einer unerwünschten proteinpopulation aus dem plasma
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US20090081157A1 (en) * 2006-01-09 2009-03-26 Richard Syd Kornbluth Immunostimulatory Combinations for Vaccine Adjuvants
EP3177601B1 (en) * 2014-08-06 2023-03-01 The Scripps Research Institute Tlr-independent small molecule adjuvants
CN107427567A (zh) * 2015-01-29 2017-12-01 宾夕法尼亚大学理事会 检查点抑制剂和疫苗组合物及其用于免疫疗法的用途
MX2017012939A (es) * 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
CR20180519A (es) * 2016-03-31 2019-03-05 Neon Therapeutics Inc Neoantígenos y métodos de su uso
US20180088749A1 (en) 2016-09-26 2018-03-29 Uber Technologies, Inc. Customized content generation for a user interface for a network service
US20180169224A1 (en) * 2016-12-12 2018-06-21 Wisconsin Alumni Research Foundation Tlr agonists for reducing activation-induced pd-1 expression on t cells and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014163684A1 (en) * 2013-04-03 2014-10-09 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2018005812A1 (en) * 2016-06-29 2018-01-04 The Scripps Research Institute Diprovocims: a new and potent class of tlr agonists

Also Published As

Publication number Publication date
IL280584B1 (en) 2025-02-01
BR112021001992A2 (pt) 2021-05-04
EP3829571B1 (en) 2025-04-09
CN113164445A (zh) 2021-07-23
US20210315992A1 (en) 2021-10-14
AU2019315952A1 (en) 2021-03-04
KR20210029280A (ko) 2021-03-15
CA3108515A1 (en) 2020-02-06
AU2025204146A1 (en) 2025-07-17
AU2025204146A9 (en) 2026-03-19
EP3829571C0 (en) 2025-04-09
EP3829571A4 (en) 2022-04-27
JP2021533134A (ja) 2021-12-02
EP3829571A1 (en) 2021-06-09
IL280584A (en) 2021-03-25
WO2020028532A1 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
EP3829571B1 (en) Adjuvant effect of the tlr1/2 agonist diprovocim synergizes with checkpoint-inhibiting antibodies to eliminate cancerous or infectious diseases
KR100717901B1 (ko) 4-1ｂｂ 및/또는 ｃｄ40의 생체내 격발을 통한 항종양ｃｔｌ 면역성 유발
EP1434596B1 (en) Enhancement of immune responses by agonist 4-1bb-antibodies
JP2546544B2 (ja) 免疫強化を促進するための方法と組成物
JP6698541B2 (ja) 細胞性の細胞傷害性免疫応答を誘導または延長する方法における使用のための医薬
JP2015529676A (ja) 作用物質および方法
AU2015205327A1 (en) Improved cell compositions and methods for cancer therapy
US20240174759A1 (en) Multispecific binding agents against cd40 and cd137 in therapy
US11479604B2 (en) Immunomodulatory peptides and methods for modulating the immune system in a subject
JP2023549112A (ja) Ｉｌ－７タンパク質とヌクレオチドワクチンの組み合わせで腫瘍を治療する方法
US20240415828A1 (en) Tlr7 agonist and combinations for cancer treatment
US20050255106A1 (en) Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40
AU2022327884A1 (en) Pharmaceutical composition and method for treatment or prevention of cancer
HK40108327A (en) Pharmaceutical composition and method for treatment or prevention of cancer
KR20160127711A (ko) 유비퀴티닐화 단백질
Sultana Studies on CD40mAb-adjuvanted conjugate vaccines.
HK1248546B (zh) Wt1抗原肽和免疫调节剂的组合用途